Case report: A pediatric case of Bickerstaff brainstem encephalitis after COVID-19 vaccination and Mycoplasma pneumoniae infection: Looking for the culprit.
Bickerstaff brainstem encephalitis
COVID-19 vaccination
Mycoplasma pneumoniae
anti-GQ1b antibody
immune-mediated diseases
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
07
2022
accepted:
25
07
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
31
8
2022
Statut:
epublish
Résumé
Bickerstaff brainstem encephalitis (BBE) is a rare, immune-mediated disease characterized by the acute onset of external ophthalmoplegia, ataxia, and consciousness disturbance. It has a complex multifactorial etiology, and a preceding infectious illness is seen in the majority of cases. Immune-mediated neurological syndromes following COVID-19 vaccination have been increasingly described. Here we report the case of a child developing BBE 2 weeks after COVID-19 vaccination. Despite nerve conduction studies and CSF analysis showing normal results, BBE was diagnosed on clinical ground and immunotherapy was started early with a complete recovery. Later, diagnosis was confirmed by positive anti-GQ1b IgG in serum. Even if there was a close temporal relationship between disease onset and COVID-19 vaccination, our patient also had evidence of a recent Mycoplasma pneumoniae infection that is associated with BBE. Indeed, the similarity between bacterial glycolipids and human myelin glycolipids, including gangliosides, could lead to an aberrantly immune activation against self-antigens (i.e., molecular mimicry). We considered the recent Mycoplasma pneumoniae infection a more plausible explanation of the disease onset. Our case report suggests that suspect cases of side effects related to COVID-19 vaccines need a careful evaluation in order to rule out well-known associated factors before claiming for a causal relationship.
Identifiants
pubmed: 36032138
doi: 10.3389/fimmu.2022.987968
pmc: PMC9411636
doi:
Substances chimiques
COVID-19 Vaccines
0
Gangliosides
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
987968Informations de copyright
Copyright © 2022 Monte, Pro, Ursitti, Ferilli, Moavero, Papetti, Sforza, Bracaglia, Vigevano, Palma and Valeriani.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Pharmacol. 2022 Mar;62(3):291-303
pubmed: 34921562
J Neurol. 2018 Jan;265(1):141-150
pubmed: 29177548
J Neurol Neurosurg Psychiatry. 2013 May;84(5):576-83
pubmed: 22984203
Neurol Sci. 2020 Jun;41(6):1605-1606
pubmed: 31897940
Front Public Health. 2020 Jul 28;8:361
pubmed: 32850592
Neurol Neuroimmunol Neuroinflamm. 2020 Sep 15;7(6):
pubmed: 32934014
J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):50-5
pubmed: 11118247
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Clin Microbiol Infect. 2022 Jan;28(1):130-134
pubmed: 34592420
PLoS Pathog. 2014 Jun 12;10(6):e1003983
pubmed: 24945969
Cell Mol Immunol. 2020 Apr;17(4):313-322
pubmed: 32152553
J Neurol. 2008 May;255(5):674-82
pubmed: 18274803
J Child Neurol. 2006 Jun;21(6):533-4
pubmed: 16948943
Brain. 2022 Feb 18;:
pubmed: 35180300
Infect Immun. 2002 Mar;70(3):1202-8
pubmed: 11854201
NPJ Vaccines. 2019 Sep 24;4:39
pubmed: 31583123
Ther Adv Neurol Disord. 2020 Aug 30;13:1756286420952901
pubmed: 32944082
Nat Rev Neurol. 2014 Sep;10(9):537-44
pubmed: 25072194